Introduction
============

The lung cancer is the leading cause of death worldwide. In 2009, molecular target therapy such as epidermal growth factor receptor (EGFR) inhibitors was recognized as a potential treatment for certain types of lung cancer [@B1], [@B2]. The effect of EGFR tyrosine kinase inhibitors (EGFR-TKI) has been linked to EGFR mutations in cancer cells, most of which are exon 19 deletions followed by exon 21 L858R mutations [@B3]-[@B5]. Current studies on EGFR mutations have shown a higher tendency of EGFR mutations in adenocarcinoma, such as in female cancer patients with no smoking history [@B6]-[@B8]. Regarding racial differences in EGFR mutations, EGFR mutations have been observed in approximately 12%-15% of Caucasian patients with lung adenocarcinoma, but the rate can be as high as 60% in Asian populations [@B5], [@B9]. For EGFR-TKIs, the most frequently studied drugs are gefitinib and erlotinib [@B4], [@B10]. Nevertheless, even in patients with EGFR mutations, the treatment efficacy of these drugs is only approximately 60%-70% [@B11]. Therefore, identifying biomarkers that enhance the treatment efficacy of these drugs is crucial.

Survivin, also known as BIRC6, located on human chromosome 17q2, is a member of the inhibitors of apoptosis protein (IAP) family and its key function is apoptosis suppression [@B12], [@B13]. Researchers have found that in the mitochondria, survivin directly suppresses Bax- and Fas-induced apoptosis and blocks the apoptosis pathway by binding to activated capspase-3 and caspase-7 proteins [@B14], [@B15]. In addition to apoptosis suppression, an increasing number of studies are showing that survivin is tumor-specific because it is expressed in large quantities in tumor tissues and is closely associated with tumor differentiation, proliferation, and metastasis [@B16], [@B17]. In non-small-cell lung cancer (NSCLC), high expression of survivin indicates a poor clinical prognosis [@B18]-[@B20]. Other studies have suggested that suppressing survivin in lung cancer cells can reduce lung cancer metastasis and invasion [@B21]-[@B23]. Some researchers have indicated that in EGFR-mutated lung cancer cell lines, EGFR-TKIs may induce apoptosis by suppressing survivin expression [@B24]-[@B26]. A study by Shi showed that survivin expression in the blood is a reliable marker of EGFR-TKI treatment efficacy in patients with lung cancer [@B26].

Some studies have reported that single nucleotide polymorphism (SNP) of *survivin* promoters alters protein expression by affecting the functions of transcription factors [@B27]-[@B29]. In fact, the SNP of *survivin* influences the severity and prognosis of many types of cancer including stomach, colorectal, and lung cancer [@B27], [@B30]-[@B32]. Although the SNP of *survivin* -31 G/C and other SNPs that can affect survivin expression, the association between the SNP of survivin and EGFR mutations in NSCLC still needs to be verified. Moreover, the high EGFR mutation rate, including L858R in exon 21 or in-frame deletion in exon 19, was found in Taiwan populations. Therefore, the present study examined the association between *survivin* SNP and EGFR mutations and explored the association between survivin SNP and the clinicopathological characteristics in NSCLC.

Methods
=======

Patient Specimens
-----------------

In 2012-2014, we recruited 360 patients with lung cancer, including 291 adenocarcinoma lung cancer and 69 squamous cell carcinoma lung cancer patients, at Cheng-Ching General Hospital in Taichung, Taiwan. Demographic characteristics and medical information of the patients, including TNM clinical staging, primary tumor size, lymph node involvement, and histologic grade, was obtained from their medical records. Exons 18-21 of the EGFR gene were amplified using polymerase chain reaction and subsequently sequenced as described previously [@B33]. This study was approved by the Institutional Review Board of Cheng-Ching General Hospital (No: HP120009) and informed consent was obtained from all subjects.

Genomic DNA extraction and *survivin* genotyping
------------------------------------------------

DNA was extracted from buffy coats using a QIAamp DNA blood mini kits (Qiagen, Valencia, California) as described in detail previously [@B34]. DNA was dissolved in TE buffer and used as the template in polymerase chain reactions. Allelic discrimination of *survivin* -31, +9194, and +9809 gene polymorphism was assessed with the ABI StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and analyzed using SDS vers. 3.0 software (Applied Biosystems), with the TaqMan assay [@B28], [@B29].

Statistical analysis
--------------------

The distributions of demographic characteristics and genotype frequencies between adenocarcinoma lung cancer and squamous cell carcinoma lung cancer as well as clinicopathological features in different genotypes were analyzed by χ2-test. The odds ratio and 95% CIs of the association between the genotype frequencies and EGFR mutation risk and the clinical pathological characteristics were estimated using multiple logistic regression models after controlling for other covariates. A p value of \<0.05 was considered statistically significant. The data were analyzed with SAS statistical software (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patients\' characteristics and distribution of lung cancer
----------------------------------------------------------

Total 360 patients were enrolled in this study. The demographics and clinical characteristics of patients were shown in Table [1](#T1){ref-type="table"}. The average age of patients was 66 years. The gender distribution in patients were 205 male (56.9%) and 155 female (44.5%). In all patients, the percentage of adenocarcinoma and squamous cell carcinoma were 80.8% (291/360) and 19.2% (69/360), respectively. Moreover, female patients possessed higher frequency (male vs. female = 49.5% vs. 50.5%) in the adenocarcinoma. For the cigarette smoking status, it was shown 58.6% (205/360) never-smokers and 41.4% (149/360) ever-smokers. Furthermore, never-smoking patients had higher frequency (never-smokers vs. ever-smokers = 66.7% vs. 33.3%) in the adenocarcinoma, while it was shown lower frequency (never-smokers vs. ever-smokers = 24.6% vs. 75.4%) in the squamous cell carcinoma (p\<0.001).

Associations between *survivin* SNPs and lung cancer
----------------------------------------------------

The distribution frequency of *survivin* -31, +9194 and +9809 genotypes in the lung adenocarcinoma and squamous cell carcinoma are shown in Table [2](#T2){ref-type="table"}. The alleles with the highest distribution frequency for -31, +9194 and +9809 of *survivin* in recruited patients with NSCLC were heterozygous C/G, homozygous A/A, and heterozygous T/C, respectively. After adjusting variables, there was no significant difference between the lung adenocarcinoma and squamous cell carcinoma with polymorphisms of the *survivin* -31, +9194 and +9809 genotypes when compared with wild-type individuals.

Patient\'s characteristics and distribution of *EGFR* mutations in adenocarcinoma
---------------------------------------------------------------------------------

We further investigated the associations between *EGFR* mutations and patient\'s characteristics. As shown in Table [3](#T3){ref-type="table"}, both substitution mutation (L858R) and Exon 19 in-frame deletion mutations were shown higher percentage in female patients (male vs. female = 19.2% vs. 80.8% and 44.9% vs. 55.1%, respectively) and in never-smoker patients (never-smokers vs. ever-smokers = 88.5% vs.11.5% and 73.5% vs. 26.5%, respectively). The data of distribution were shown significantly different between control (wild-type) and*EGFR* mutations in gender (*p*\<0.05) and cigarette smoking status (*p*\<0.05). These results indicated that *EGFR* mutations were associated with gender and cigarette smoking status.

Associations between *survivin* SNPs and EGFR mutations in adenocarcinoma
-------------------------------------------------------------------------

To clarify the association between the polymorphism of *survivin*gene and EGFR mutation, the distribution frequency of *survivin* (-31, +9194 and +9809) gene genotypes and *EGFR* mutation type in lung adenocarcinoma patients were estimated. As the results shown in Table [4](#T4){ref-type="table"}, GC and GC+CC genotypes of*survivin* -31 were shown significantly association with *EGFR* mutation in lung adenocarcinoma patients (AOR = 3.622, 95% CI = 1.158-11.325 and AOR = 3.498, 95% CI = 1.171-10.448, respectively). Moreover, the results of Table [5](#T5){ref-type="table"} were shown that GC+CC genotypes of *survivin* -31 were shown slightly association with L858R mutation in lung adenocarcinoma patients (AOR = 0.5187, 95% CI = 0.935-2.242). These results indicated the polymorphism of *survivin -31* genes were associated with EGFR mutation in adenocarcinoma patients.

Associations between *survivin* SNPs and clinicopathological characteristics of lung cancer

To revealed the association between polymorphisms of *survivin* gene and different clinical stage of lung cancer in different EGFR mutation of patients. As shown in Table [6](#T6){ref-type="table"}, CG+GG genotype of *survivin -31* was shown significantly association with clinical advanced stage in lung adenocarcinoma patients with exon 19 mutations (OR = 4.800, 95% CI = 1.305-17.658; p=0.014). These findings indicated that the polymorphisms of *survivin -31* may associated with clinical advanced stage of lung cancer.

Discussion
==========

Survivin is an apoptosis-suppressing protein and its association with many types of cancer (including lung cancer) has been well documented [@B30], [@B31], [@B35], [@B36]. However, few studies have investigated how SNP is related to EGFR mutations or prognosis in lung cancer. The present study revealed that *survivin* -31 polymorphism may be associated with EGFR mutations, particularly L858R mutations. Furthermore, in patients with exon 19 mutations, *survivin* -31 polymorphisms have an increased incidence to develop late-stage. To our best knowledge, the present study is the first reports to show a link between *survivin*SNP and EGFR mutations in patients with lung cancer.

High expression of survivin in the blood and tissues of patients with lung cancer is also associated with clinicopathological characteristics, including metastasis and low survival rates [@B26], [@B37]-[@B39]. Previous studies have shown that high survivin expression in the blood of lung cancer patients undergoing EGFR-TKI treatment is associated with a poor prognosis [@B26]. The present study also identified an association between *survivin* -31 polymorphism and the EGFR mutation statues, suggesting that EGFR mutations may impair the effect of TKIs; that is, patients with *survivin* -31G/G genotypes may have higher survivin protein expression. The results were consistent with previous reports that an association between SNP of *survivin*and lung cancer as well as higher transcriptional activity in the C/C genotype, the latter of which may elevate survivin protein expression [@B31], [@B40].

In addition to linking the SNP of *survivin* -31C/G to the incidence of lung cancer, previous studies have also revealed some clinical manifestations related to *survivin* -31 C/G polymorphism [@B36], [@B41]. For example, Javid et al. found that *survivin* -31C/C in lung cancer patients was associated with a poor overall survival rate [@B41], and Rosato et al. showed that the -31 C/C genotype was related to node metastasis and patient survival [@B36]. Moreover, Tao et al. showed that survivin 9386 C\>T polymorphisms are potential independent prognostic factors in NSCLC patients treated with platinum-based chemotherapy [@B42]. The present study showed that *survivin* -31C/C was stage-related in patients with EGFR exon 19 mutations. However, this relation was not observed in the EGFR wild type or in lung cancer patients with L858R mutations. A possible explanation is that the effect of survivin differs according to the type of EGFR mutation. For example, Okamoto et al. demonstrated that gefitinib in EGFR-mutated cells modulates cell survival by suppressing survivin expression via the PI3K-AKT signaling pathway [@B25]. Another possibility is that EGFR L858R and exon 19 mutations exists different oncogenic ability [@B43]. Although the previous study showed exon 19 to have a higher oncogenic ability compared with that of L858R [@B43], the role of survivin in these two distinct mutation processes requires further examination.

In conclusion, our results showed that *survivin* genetic variants are related to EGFR mutation in lung adenocarcinoma patients and might contribute to pathological development to NSCLC. The findings provide a hint for the genesis of EGFR mutations.
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###### 

Demographics and clinical characteristics of 360 patients affected with lung adenocarcinoma and lung squamous cell carcinoma.

  --------------------------------------------------------------------------------------------
  Variable                       All cases\      Adenocarcinoma\   Squamous cell\   p value
                                 (N=360) n (%)   (N=291) n (%)     carcinoma\       
                                                                   (N=69) n (%)     
  ------------------------------ --------------- ----------------- ---------------- ----------
  **Age**                                                                           

  \<30                           3 (0.8%)        3 (1.0%)          0 (0%)           p=0.963

  30-39                          5 (1.4%)        4 (1.4%)          1 (1.4%)         

  40-49                          35 (9.7%)       28 (9.6%)         7 (10.1%)        

  50-59                          76 (21.1%)      63 (21.6%)        13 (18.8%)       

  60-69                          78 (21.7%)      61 (21.0%)        17 (24.6%)       

  ≥70                            163 (45.3%)     132 (45.4%)       31 (44.9%)       

  Mean ± SD                      66.31 ± 13.89   66.21 ± 13.91     66.71 ± 13.92    p=0.788

  **Gender**                                                                        

  Male                           205 (56.9%)     144 (49.5%)       61 (88.4%)       p\<0.001

  Female                         155 (43.1%)     147 (50.5%)       8 (11.6%)        

  **Cigarette smoking status**                                                      

  Never-smoker                   211 (58.6%)     194 (66.7%)       17 (24.6%)       p\<0.001

  Ever-smoker                    149 (41.4%)     97 (33.3%)        52 (75.4%)       

  PPK                            48.83 ± 23.84   45.84 ± 21.79     54.42 ± 26.57    p=0.036

  **Disease stage**                                                                 

  IA                             35 (9.7%)       33 (11.3%)        2 (2.9%)         p\<0.001

  IB                             45 (12.5%)      40 (13.7%)        5 (7.2%)         

  IIA                            24 (6.7%)       18 (6.2%)         6 (8.7%)         

  IIB                            9 (2.5%)        6 (2.1%)          3 (4.3%)         

  IIIA                           41 (11.4%)      30 (10.3%)        11 (15.9%)       

  IIIB                           58 (16.1%)      33 (11.3%)        25 (36.2%)       

  IV                             148 (41.1%)     131 (45.0%)       17 (24.6%)       
  --------------------------------------------------------------------------------------------

###### 

Distribution frequency of *survivin* genotypes in 291 lung adenocarcinoma and 69 lung squamous cell carcinoma.

  -------------------------------------------------------------------------------------------------------------------------------
  Variable          adenocarcinoma (N=291) (%)   squamous cell carcinoma (N=69) (%)   OR (95% CI)           AOR (95% CI)
  ----------------- ---------------------------- ------------------------------------ --------------------- ---------------------
  ***survivin***\                                                                                           
  **-31**                                                                                                   

  CC                91 (31.3%)                   22 (31.9%)                           1.00                  1.00

  CG                137 (47.1%)                  30 (43.5%)                           0.906 (0.492-1.668)   0.776 (0.329-1.828)

  GG                63 (21.6%)                   17 (24.6%)                           1.116 (0.549-2.270)   0.825 (0.298-2.281)

  CG+GG             200 (68.7%)                  47 (68.1%)                           0.972 (0.553-1.708)   0.792 (0.356-1.762)

  ***survivin***\                                                                                           
  **+9194**                                                                                                 

  AA                172 (59.1%)                  43 (62.3%)                           1.00                  1.00

  AG                98 (33.7%)                   19 (27.5%)                           0.776 (0.428-1.405)   1.291 (0.531-3.138)

  GG                21 (7.2%)                    7 (10.1%)                            1.333 (0.532-3.340)   3.031 (0.839-3.138)

  AG+GG             119 (40.9%)                  26 (37.7%)                           0.874 (0.509-1.500)   1.627 (0.734-3.606)

  ***survivin***\                                                                                           
  **+9809**                                                                                                 

  TT                108 (37.1%)                  25 (36.2%)                           1.00                  1.00

  TC                132 (45.4%)                  27 (39.1%)                           0.884 (0.485-1.611)   0.864 (0.388-1.923)

  CC                51 (17.5%)                   17 (24.7%)                           1.440 (0.715-2.901)   0.763 (0.281-2.075)

  TC+CC             183 (62.9%)                  44 (63.8%)                           1.039 (0.602-1.792)   0.831 (0.396-1.743)
  -------------------------------------------------------------------------------------------------------------------------------

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age, gender and cigarette smoking status.

###### 

Demographics and clinical characteristics of 190 patients in lung adenocarcinoma with EGFR mutation status.

  ---------------------------------------------------------------------------------------------------
  Variable                       Wild type\      L858R\          In-frame deletion\   Others\
                                 (N=82) n (%)    (N=52) n (%)    (N=49) n (%)         (N=7) n (%)
  ------------------------------ --------------- --------------- -------------------- ---------------
  **Age**                                                                             

  \<30                           2 (2.4%)        0 (0%)          1 (2.0%)             0 (0%)

  30-39                          2 (2.4%)        0 (0%)          1 (2.0%)             0 (0%)

  40-49                          10 (12.2%)      5 (9.6%)        8 (16.3%)            0 (0%)

  50-59                          14 (17.1%)      7 (13.5%)       14 (28.6%)           2 (28.6%)

  60-69                          19 (23.2%)      13 (25.0%)      10 (20.4%)           0 (0%)

  ≥70                            35 (42.7%)      27 (51.9%)      15 (30.6%)           5 (71.4%)

  Mean ± SD                      65.16 ± 15.06   68.17 ± 12.62   60.98 ± 13.56^b^     71.57 ± 12.04

  **Gender**                                                                          

  Male                           52 (63.4%)      10 (19.2%)^a^   22 (44.9%)^a,b^      4 (57.1%)

  Female                         30 (36.6%)      42 (80.8%)      27 (55.1%)           3 (42.9%)

  **Cigarette smoking status**                                                        

  Never-smoker                   35 (42.7%)      46 (88.5%)^a^   36 (73.5%)^a^        4 (57.1%)

  Ever-smoker                    47 (57.3%)      6 (11.5%)       13 (26.5%)           3 (42.9%)

  PPK                            51.89 ± 21.46   40.00 ± 26.08   29.00 ± 17.29^a^     56.67 ± 16.07

  **Disease stage**                                                                   

  IA                             8 (9.8%)        4 (7.7%)        5 (10.2%)            1 (14.3%)

  IB                             6 (7.3%)        8 (15.4%)       7 (14.3%)            1 (14.3%)

  IIA                            4 (4.9%)        3 (5.8%)        3 (6.1%)             0 (0%)

  IIB                            0 (0%)          0 (0%)          0 (0%)               0 (0%)

  IIIA                           11 (13.4%)      7 (13.5%)       2 (4.1%)             0 (0%)

  IIIB                           14 (17.1%)      5 (9.6%)        3 (6.1%)             1 (14.3%)

  IV                             39 (47.6%)      25 (48.1%)      29 (59.2%)           4 (57.1%)
  ---------------------------------------------------------------------------------------------------

^a^Significant difference compare with wild type group, p value\<0.05.

^b^Significant difference compare with L858R group, p value\<0.05.

###### 

Distribution frequency of *survivin* genotypes of 82 EGFR wild type and 108 EGFR mutation type in lung adenocarcinoma patients.

  -----------------------------------------------------------------------------------------------------------------------
  Variable          Wild type (N=82) n (%)   Mutation type (N=108) (%)   OR (95% CI)             AOR (95% CI)
  ----------------- ------------------------ --------------------------- ----------------------- ------------------------
  ***survivin***\                                                                                
  -31                                                                                            

  GG                22 (26.8%)               13 (12.0%)                  1.00                    1.00

  GC                39 (47.6%)               58 (53.7%)                  2.517 (1.135-5.583)\*   3.622 (1.158-11.325)\*

  CC                21 (25.6%)               37 (34.3%)                  2.982 (1.249-7.117)\*   3.262 (0.921-11.549)

  GC+CC             60 (73.2%)               95 (88.0%)                  2.679 (1.256-5.718)\*   3.498 (1.171-10.448)\*

  ***survivin***\                                                                                
  **+9194**                                                                                      

  AA                51 (62.6%)               54 (50.0%)                  1.00                    1.00

  AG                26 (31.7%)               44 (40.7%)                  1.598 (0.862-2.964)     1.363 (0.550-3.376)

  GG                5 (6.1%)                 10 (9.3%)                   1.889 (0.604-5.904)     1.932 (0.348-10.743)

  AG+GG             31 (37.8%)               54 (50.0%)                  1.645 (0.917-2.951)     1.418 (0.235-8.571)

  ***survivin***\                                                                                
  **+9809**                                                                                      

  TT                30 (36.6%)               43 (39.8%)                  1.00                    1.00

  TC                38 (46.3%)               48 (44.4%)                  0.881 (0.469-1.657)     0.561 (0.229-1.376)

  CC                14 (17.1%)               17 (15.7%)                  0.847 (0.363-1.977)     0.631 (0.170-2.338)

  TC+CC             52 (63.4%)               65 (60.2%)                  0.872 (0.483-1.576)     1.125 (0.321-3.944)
  -----------------------------------------------------------------------------------------------------------------------

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age and gender.

\*p \< 0.05.

###### 

The associations between the polymorphisms of survivin and the EGFR hotspot mutations in lung adenocarcinoma patients.

  ------------------------------------------------------------------------------------------------------------------------------------
  Variable          Wild type          L858R            Exon 19 in-frame deletion                       
  ----------------- ------------------ ---------------- ------------------------------ ---------------- ------------------------------
                    **(N=82) n (%)**   **(N=52) (%)**   **AOR (95% CI)**               **(N=49) (%)**   **AOR (95% CI)**

  ***survivin***\                                                                                       
  **-31**                                                                                               

  GG                22 (26.8%)         6 (11.5%)        1.00                           7 (14.3%)        1.00

  GC                39 (47.6%)         26 (50.0%)       5.346 (0.906-31.537) p=0.064   27 (55.1%)       2.756 (0.570-13.311) p=0.207

  CC                21 (25.6%)         20 (38.5%)       4.948 (0.752-32.575) p=0.096   15 (30.6%)       1.633 (0.245-10.872) p=0.612

  GC+CC             60 (73.2%)         46 (88.5%)       5.187 (0.935-2.242) p=0.057    42 (85.7%)       2.460 (0.524-11.539) p=0.254

  ***survivin***\                                                                                       
  **+9194**                                                                                             

  AA                51 (62.6%)         26 (50.0%)       1.00                           23 (46.9%)       1.00

  AG                26 (31.7%)         22 (42.3%)       1.946 (0.495-7.650) p=0.341    21 (42.9%)       2.458 (0.650-9.291) p=0.185

  GG                5 (6.1%)           4 (7.7%)         1.241 (0.099-15.603) p=0.867   5 (10.2%)        2.593 (0.205-32.738) p=0.461

  AG+GG             31 (37.8%)         26 (50.0%)       0.638 (0.047-8.653) p=0.735    26 (53.1%)       2.481 (0.711-8.650) p=0.154

  ***survivin***\                                                                                       
  **+9809**                                                                                             

  TT                30 (36.6%)         16 (30.8%)       1.00                           24 (49.0%)       1.00

  TC                38 (46.3%)         30 (57.5%)       0.967 (0.265-3.528) p=0.960    16 (32.7%)       0.301 (0.087-1.042) p=0.058

  CC                14 (17.1%)         6 (11.5%)        0.312 (0.042-2.308) p=0.254    9 (18.4%)        0.493 (0.080-3.019) p=0.444

  TC+CC             52 (63.4%)         36 (69.2%)       0.323 (0.051-2.050) p=0.231    25 (51.0%)       0.339 (0.108-1.063) p=0.064
  ------------------------------------------------------------------------------------------------------------------------------------

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age and gender.

###### 

Associations between polymorphic genotypes of *survivin* -31 and clinicopathologic characteristics of lung cancer.

                                       Clinical Stage                                        
  ------------------------------------ ---------------- ------------- ---------------------- -----------
  **All cases (N=360)**                (N=212)          (N=148)                              
  *survivin* -31 CC                    75 (35.4%)       38 (25.7%)    1.00                   
  *survivin* -31 CG+GG                 137 (64.6%)      110 (74.3%)   1.585 (0.996-2.520)    p=0.051
                                                                                             
  **adenocarcinoma (N=291)**           (N=160)          (N=131)                              
  *survivin* -31 CC                    56 (35.0%)       35 (26.7%)    1.00                   
  *survivin* -31 CG+GG                 104 (56.0%)      96 (73.3%)    1.477 (0.891-2.448)    p=0.129
                                                                                             
  **squamous cell carcinoma (N=69)**   (N=52)           (N=17)                               
  *survivin* -31 CC                    19 (36.5%)       3 (17.6%)     1.00                   
  *survivin* -31 CG+GG                 33 (63.5%)       14 (82.4%)    2.687 (0.684-10.561)   p=0.147
                                                                                             
  **Wild type (N=82)**                 (N=43)           (N=39)                               
  *survivin* -31 CC                    10 (23.3%)       11 (28.2%)    1.00                   
  *survivin* -31 CG+GG                 33 (76.7%)       28 (71.8%)    0.771 (0.286-2.083)    p=0.608
                                                                                             
  **L858R (N=52)**                     (N=27)           (N=25)                               
  *survivin* -31 CC                    12 (44.4%)       8 (32.0%)     1.00                   
  *survivin* -31 CG+GG                 15 (55.6%)       17 (68.0%)    1.700 (0.548-5.275)    p=0.327
                                                                                             
  **In-frame deletion (N=49)**         (N=20)           (N=29)                               
  *survivin* -31 CC                    10 (50.0%)       5 (17.2%)     1.00                   
  *survivin* -31 CG+GG                 10 (50.0%)       24 (82.8%)    4.800 (1.305-17.658)   p=0.014\*

\*p \< 0.05.
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